A major way of delivering CRISPR into the body is through inactivated viruses that can be programmed to attach themselves to target cells. The challenge is that viruses can’t be engineered to be 100 ...

This research roundup discusses researchers’ attempts to find a treatment for a “brain fog” that comes with CAR T-Cell therapy and a new use of CRISPR to deliver RNA segments to cellular ...

CRISPR Therapeutics AG CRSP announced that its wholly-owned allogeneic CAR-T cell therapy, CTX110, targeting CD19+ B-cell malignancies, has been granted Regenerative Medicine Advanced Therapy ...

In modern functional genomics, understanding how specific genes control cellular behavior requires both targeted intervention and high-resolution analysis. That''s where Perturb-Seq comes in-a method ...

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T cell malignancies. Blood. May 30, 2025. Ghobadi has provided consulting for Wugen.

CRISPR Therapeutics is currently studying CTX130TM, an investigational allogeneic CAR-T cell therapy, in patients with CD70-expressing tumors, including clear cell renal cell carcinoma and B and T ...

Cat1 forms filament networks to degrade NAD + during the type III CRISPR-Cas antiviral response. Science, 2025; DOI: 10.1126/science.adv9045 ...

Often our cells' DNA repair machinery makes mistakes. Zayner says, "In this case, when CRISPR targeted this gene and cut it, in the repair process, occasionally an extra base pair would be added.

CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR ...